Next-generation, selective kinase medicines
Our proprietary scientific platform enables us to rapidly and reproducibly design medicines that selectively target kinase drivers of disease, enabling improved potency, less off-target activity and an increased probability of clinical success.
Blueprint Medicines’ avapritinib, an investigational KIT and PDGFRA inhibitor for advanced gastrointestinal stromal tumors (GIST) and systemic mastocytosis (SM)
Sutent® (sunitinib), an FDA-approved multi-kinase inhibitor for advanced GIST
Rydapt® (midostaurin), an FDA-approved multi-kinase inhibitor for advanced SM
Kinome illustrations reproduced courtesy of Cell Signaling Technology, Inc. (CSTI).
A focused strategy
Our research focuses on kinase targets where we believe our technology can lead to meaningful improvements in treatment.
Well-recognized kinases that are difficult to target with existing technologies
Mutant kinases that have become resistant to current treatments
New targets identified with our computational and cell biology expertise